Systematic approach to evaluate clinical trials in pregnancy serious disease

Authors: Ashutosh Rudraksh MS and Lijun Cheng Ph.D*

*Contact: lijun.cheng@osumc.edu

INTRODUCTION

- Facilitating inclusion of pregnant women in clinical research could help answer important questions about the effects of medication use during pregnancy.
- Understanding the ways in which pregnancy alters pharmacokinetics and drug effects is crucial for optimizing maternal and fetal health outcomes.

AIM

- Objective: Gather existing information on the drug from medical literature, including clinical trials, observational studies, and case reports specifically focusing on use in pregnancy.
- Sources: Use databases like <u>clinical</u>
 <u>trials(https://clinicaltrials.gov/)</u>, PubMed, Embase, and
 Cochrane Library to find relevant studies and reviews for
 drug treatment and associated targets.
- Searching pregnancy related disease and associated treatments, we will focus on the following conditions (15 diseases): (1) Pre-eclampsia/eclampsia (PE/E), (2) Hyperemesis Gravidarum, (3) Gestational Diabetes, (4) Intrahepatic Cholestasis of Pregnancy (ICP), (5) Placenta Previa, (6) Anemia,(7) Preterm Labor/Birth (PTL/PTB), (8) Fetal Growth Restriction (FGR), (9) Obstetric Cholestasis, (10) Maternal Vascular Malperfusion (MVM), (11) Preterm Premature Rupture of Membranes (PPROM), (12) Post-partum hemorrhage (PPH), (13) intrauterine growth restriction (IUGR), and (14) fetal distress (15) gestational hypertension.

DATA COLLECTION

Searching and collecting treatment drug options and their targets during pregnancy

- Clinical Trials and Drug Databases Search:
 Conducted searches on Clinical Trials.gov
 (https://clinicaltrials.gov/)using drug names as keywords
 for 15 pregnancy-related diseases. Extracted drug
 indications and targets from DrugBank
 (https://go.drugbank.com/)using Natural Language
 Program (NLP).
- Python and Web Scraping: Utilized Python scripts for web scraping and automated data retrieval from ClinicalTrials.gov and DrugBank.

- Systematic Data Organization: Structured the collected data into a comprehensive pregnancy diseasedrug-target database, organizing by disease, drug, and target.
- CSV File Structure: Compiled the data into a CSV file, detailing drug names, associated diseases, clinical trial records, and drug targets for easy access and analysis. (Table 1)

Table 1: Example dataset



DATA ANALYSIS

Statistical Analysis

- Data Analysis Tools: The collected data was analyzed using the SPSS statistical software (version SPSS 20.0).
 This involved using various statistical methods to interpret the data accurately.
- Statistical Methods: Count data were expressed as percentages (%), while measurement data were presented as mean ± standard deviation (S.D.). Comparisons between groups were performed using independent samples t-test or Mann–Whitney U-test, with a significance level set at α = 0.05 (p ≤ 0.05).

DRUG Mechanism of Action Enrichment to 15 Diseases

- Each disease associated drugs and their targets are used pathway enrichment analysis by DAVID Functional Annotation Bioinformatics Microarray Analysis Tool (http://david.ncifcrf.gov)
- DAVID Functional Annotation Bioinformatics Microarray Analysis (Fig. 3) visualizes the enriched pathways for drug targets in the 15 diseases, clearly demonstrating the impact of the drugs on specific biological pathways and aiding in understanding their mechanisms of action.

RESULTS

Result 1: Data distribution of drug-disease from Clinical Trials associated with Pregnancy

Figure 1. Disease Distribution to Clinical Trails





Figure 2. Drug distribution to Clinical Trails in disease during



Result 2: Targets of drugs enrichment in KEGG pathways in Hyperemesis Gravidarum

 KEGG Pathway Analysis: The targets of drugs used in the treatment of Hyperemesis Gravidarum were analyzed for enrichment in KEGG pathways using the DAVID Functional Annotation Tool. This analysis identifies significant biological pathways impacted by these drugs. Figure 3 visualizes the enriched pathways for drug targets in the diseases Hyperemesis Gravidarum from KEGG pathways.

Figure 3: Pathway Enrichment Analysis of Drug Targets in Hyperemesis Gravidarum

Celegray 1	Term	0.00	Serve	Conf	3.1	# Neber	Centerele
KEGG_PATHWAY	Calcium signalins partners	10.1	_	45	20,0	1-86-30	£35-32
KEGG_PATHWAY	Chemical carchimenesis - recaptor activation	III i	-	28	11.7	7.90:13	8.75-13
KEGQ_PATHWAY	Sonin secretical	ET i		18	9.8	1.1E-14	9.7E-13
KEGEL PATHWAY	MACK streams settings	EI i		311	15.5	1.01-13	7,12-12
KESIS_PATHWAY	Advonost, signalina in conformosytes	KE i		21	11.2	2.1F13	1.15-11
KODGEL PATHWAY	Endineers incomes	AT. i		465	143	4,081-13	1.79-11
KEGG_PATHWAY	Neuroactive listand, recently, interaction	RT i		32	15.5	4.1E-13	1.50-10
KEEKS, DATHWAY	Cortoch scrakes suthern	RE i	_	75	10.2	1.76-11	5.4E-18
KEGIS PATHWAY	pGPB-PKG standard pathway	KE i		21	10.2	8.7E-11	2.00-9
KESS DETHWAY	Hyantoonic cardionystathy	KE i		14	6.8	6.06-6	1666
KEGG_PATHWO	Fetnol metabolism	KT i		12	5.0	7,36-6	1.70-6
KEGIG_IMTHWAT	Wacola: amooth muscle contraction	III i		15	7,1	1.4E7	7,AE 6
KESG_PATRWAY	Solvary, secretian	RI i		12	6.)).牲力	X.7E-6
KEGKS_PATHWAY	GAMP stanging pathogs	ET.	-	19	9,3	4,300	0.150
KROG, PATHWAY	Gelit secretar	RE I		11	54	4.7E-7	5.26-6
	KEGO, JATHWAY	Colorum State SCOL, ASSAULT Colorum projects authors SCOL, ASSAULT Colorum projects authors SCOL, ASSAULT Colorum projects activation SCOL, ASSAULT Colorum activation SCOL, ASSAULT SCOLUM activation SC	PECC, JAPANO Cickun speaks and make: III (200, JAPANO Cickun speaks and make a chorton: III (200, JAPANO Cickun speaks and make a chorton: III (200, JAPANO Siden speaks) III (200, JAPANO Siden speaks) III (200, JAPANO Cickun speaks and speaks a chorton: III (200, JAPANO Cickun speaks and speaks a chorton: III (200, JAPANO Cickun speaks and speaks a chorton: III (200, JAPANO Cickun speaks and speaks a chorton: III (200, JAPANO Cickun speaks and speaks a chorton: III (200, JAPANO Cickun speaks and speaks a chorton: III (200, JAPANO Cickun speaks and speaks and speaks a chorton: III (200, JAPANO Cickun speaks and speaks a	PECC, JAPANNO Cickun squalita strahese III PECC, JAPANNO Cickun squalita strahesenin menter achinistis III PECC, JAPANNO Fichi succeliat III (200, JAPANN		NEOL ANNINO Calcium Regulatio purbase	1000_ANNIANO Calcum Separks unabou

CONCLUSIONS

Significance of Data Extraction and Analysis: Using web scraping and NLP tools, we addressed gaps in drug information for pregnant women, improving understanding for better-targeted therapies and clinical

Study Findings: We created a comprehensive database of pregnancy-related disease-drug-target information and identified key pathways through pathway enrichment analysis.

Implications and Future Directions: The insights aim to optimize drug therapies, enhance maternal and fetal health outcomes, and support safer clinical practices, with ongoing research to refine the database.

REFERENCE

[1] Database for Annotation, Visualization, and Integrated Discovery, Dennis, G., Sherman, B.T., Hosack, D.A. et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4, R80 (2003).
[2] Winn VD, Gormley M, Paquet AC, Kjøer-Sorensen K, Kramer A, Rumer KK, Halmov-Kochman R, Yeh RF, Overgaard MT, Varki A, Oxvig C, Fisher SJ. Severe preeclampsia-related changes in gene expression at the maternal-fetal interface include salle acti-binding immunojobulin-like lectin-6 and pappalysin-2. Endocrinology. 2009 Jan;150(1):452-82.

